

26. Ferraro PM, Bargagli M. Dietetic and lifestyle recommendations for stone formers. *Arch Esp Urol*. 2021; 74(1): 112–22.
27. Yachantha C, Hossain RZ, Yamakawa K, et al. Effect of potassium depletion on urinary stone risk factors in Wistar rats. *Urol Res* [Internet]. 2009; 37(6): 311–6. Available from: <http://dx.doi.org/10.1007/s00240-009-0220-6>.
28. Witting C, Langman CB, Assimos D, et al. Pathophysiology and treatment of Enteric hyperoxaluria. *Clin J Am Soc Nephrol* [Internet]. 2021; 16(3): 487–95. Available from: <http://dx.doi.org/10.2215/cjn.08000520>.
29. Lorenz EC, Lieske JC, Seide BM, et al. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. *Am J Transplant* [Internet]. 2014; 14(6): 1433–8. Available from: <http://dx.doi.org/10.1111/ajt.12706>.
30. Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial. *Am J Kidney Dis* [Internet]. 2023; 81(2): 145-155.e1. Available from: <http://dx.doi.org/10.1053/j.ajkd.2022.05.012>.
31. Perazella MA, Herlitz LC. The crystalline nephropathies. *Kidney Int Rep* [Internet]. 2021; 6(12): 2942–57. Available from: <http://dx.doi.org/10.1016/j.ekir.2021.09.003>.
32. Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. *Nephrol Dial Transplant* [Internet]. 2012; 27(12): 4273–87. Available from: <http://dx.doi.org/10.1093/ndt/gfs493>.
33. Emmett MA. Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis. [Internet]. Uptodate.com. [cited 2024 Aug 8]. Available from: <https://www.uptodate.com/contents/etiology-and-diagnosis-of-distal-type-1-and-proximal-type-2-renal-tubular-acidosis>.
34. Mollerup CL. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. *BMJ* [Internet]. 2002; 325(7368): 807–807. Available from: <http://dx.doi.org/10.1136/bmj.325.7368.807>.
35. Finkelstein VA. Strategies for preventing calcium oxalate stones. *CMAJ* [Internet]. 2006; 174(10): 1407–9. Available from: <http://dx.doi.org/10.1503/cmaj.051517>.
36. Massey LK, Roman-Smith H, Sutton RAL. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. *J Am Diet Assoc* [Internet]. 1993; 93(8): 901–6. Available from: [http://dx.doi.org/10.1016/0002-8223\(93\)91530-4](http://dx.doi.org/10.1016/0002-8223(93)91530-4).
37. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. *J Urol* [Internet]. 2010; 183(6): 2244–8. Available from: <http://dx.doi.org/10.1016/j.juro.2010.02.007>.
38. Moe OW, Pearle MS, Sakhaee K. Pharmacotherapy of urolithiasis: evidence from clinical trials. *Kidney Int* [Internet]. 2011; 79(4): 385–92. Available from: <http://dx.doi.org/10.1038/ki.2010.389>.
39. Mensenkamp AR, Hoenderop GJJ, Bindels RJM. Recent advances in renal tubular calcium reabsorption. *Curr Opin Nephrol Hypertens* [Internet]. 2006; 15(5): 524–9. Available from: <http://dx.doi.org/10.1097/01.mnh.0000242179.38739.fb>.
40. Ruml LA, Pearle MS, Pak CYC. Medical therapy. *Urol Clin North Am* [Internet]. 1997; 24(1): 117–33. Available from: [http://dx.doi.org/10.1016/s0094-0143\(05\)70358-x](http://dx.doi.org/10.1016/s0094-0143(05)70358-x).
41. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. *N Engl J Med* [Internet]. 1986; 315(22): 1386–9. Available from: <http://dx.doi.org/10.1056/nejm198611273152204>.
42. Kok DJ. Metaphylaxis, diet and lifestyle in stone disease. *Arab J Urol* [Internet]. 2012; 10(3): 240–9. Available from: <http://dx.doi.org/10.1016/j.aju.2012.03.003>.